Biomarkers of AKI in Patients Receiving Daratumumab

Prior treatment

• Previous exposure to daratumumab or other anti-CD38 therapy
• Patients receiving intravenous daratumumab
• Exposure to concomitant chemotherapy which could be perceived as nephrotoxic within 30 days of receipt of daratumumab (e.g., cisplatin, mTOR inhibitors)

Other illness

• End stage renal disease (e.g, on long-term dialysis or with a kidney transplant and on long-term dialysis) at the time of starting daratumumab

Other

• Acute kidney injury defined as a ≥1.5-fold rise in baseline SCr, where baseline SCr is the lowest SCr in the 365 days preceding receipt of daratumumab, or with AKI on RRT
• Moribund patients (e.g., those expected to die in the next 30 days from the time of screening)

• Patients must be ≥ 18 years of age
• Patients can be on a clinical trial
• Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria
  • New diagnosis of systemic multiple myeloma defined as no documented history of prior multiple myeloma.
  • Further, no prior systemic treatment with anti-myeloma agent is permitted with the exception of corticosteroids for no more than 4 weeks.
  • Prior history of receiving radiation therapy for the treatment of plasmacytoma or lytic lesions, is permitted on the study.
• Patients receiving SC daratumumab
• Patients must be able to sign the informed consent
• Patients must be at risk for AKI and meet at least two of the three following criteria: age ≥65; baseline eGFR \<60; or use of NSAIDs (not including aspirin), bisphosphonates, intravenous contrast, diuretics, or RAS inhibitors in the 14 days preceding treatment initiation